Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.58% | 23.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.37% | -2.74% | |||
| Operating Income | 4.37% | 2.74% | |||
| Income Before Tax | 84.39% | -1,495.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 83.94% | -1,495.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 83.94% | -1,495.03% | |||
| EBIT | 4.37% | 2.74% | |||
| EBITDA | 4.40% | 2.78% | |||
| EPS Basic | 84.92% | -1,350.58% | |||
| Normalized Basic EPS | 85.36% | -1,356.25% | |||
| EPS Diluted | 86.10% | -123.55% | |||
| Normalized Diluted EPS | 85.19% | -1,405.23% | |||
| Average Basic Shares Outstanding | 6.62% | 9.82% | |||
| Average Diluted Shares Outstanding | 5.39% | 6.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||